{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:20:06Z","timestamp":1787019606041,"version":"build-2736575974"},"reference-count":155,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2002,11,15]]},"abstract":"<jats:p>Thrombocytopenia is a common medical problem for which the main treatment is platelet transfusion. Given the increasing use of platelets and the declining donor population, identification of a safe and effective platelet growth factor could improve the management of thrombocytopenia. Thrombopoietin (TPO), the c-Mpl ligand, is the primary physiologic regulator of megakaryocyte and platelet development. Since the purification of TPO in 1994, 2 recombinant forms of the c-Mpl ligand\u2014recombinant human thrombopoietin (rhTPO) and pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF)\u2014have undergone extensive clinical investigation. Both have been shown to be potent stimulators of megakaryocyte growth and platelet production and are biologically active in reducing the thrombocytopenia of nonmyeloablative chemotherapy. However, neither TPO has demonstrated benefit in stem cell transplantation or leukemia chemotherapy. Other clinical studies have investigated the use of TPO in treating chronic nonchemotherapy-induced thrombocytopenia associated with myelodysplastic syndromes, idiopathic thrombocytopenic purpura, thrombocytopenia due to human immunodeficiency virus, and liver disease. Based solely on animal studies, TPO may be effective in reducing surgical thrombocytopenia and bleeding, ex vivo expansion of pluripotent stem cells, and as a radioprotectant. Ongoing and future studies will help define the clinical role of recombinant TPO and TPO mimetics in the treatment of chemotherapy- and nonchemotherapy-induced thrombocytopenia.<\/jats:p>","DOI":"10.1182\/blood.v100.10.3457","type":"journal-article","created":{"date-parts":[[2002,10,30]],"date-time":"2002-10-30T14:43:16Z","timestamp":1035988996000},"page":"3457-3469","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":315,"title":["Recombinant human thrombopoietin: basic biology and evaluation of clinical studies"],"prefix":"10.1182","volume":"100","author":[{"given":"David J.","family":"Kuter","sequence":"first","affiliation":[{"name":"From the Hematology\/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Centre for Child Health Research, The University of Western Australia and Western Australian Institute for Medical Research, Perth, Western Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C. Glenn","family":"Begley","sequence":"additional","affiliation":[{"name":"From the Hematology\/Oncology Unit, Massachusetts General Hospital, Harvard Medical School, Boston, MA; and the Centre for Child Health Research, The University of Western Australia and Western Australian Institute for Medical Research, Perth, Western Australia."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"key":"2019111821285511600_B1","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S0889-8588(05)70346-4","article-title":"The thrombocytopenia of cancer: prospects for effective cytokine therapy.","volume":"10","author":"Kaushansky","year":"1996","journal-title":"Hematol Oncol Clin North Am."},{"key":"2019111821285511600_B2","first-page":"1597","article-title":"Thrombopoietin: biology and potential clinical applications.","volume":"12","author":"Prow","year":"1998","journal-title":"Oncology (Huntingt)."},{"key":"2019111821285511600_B3","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJM199212173272503","article-title":"Kinetic studies of the mechanism of thrombocytopenia in patients with human immunodeficiency virus infection.","volume":"327","author":"Ballem","year":"1992","journal-title":"N Engl J Med."},{"key":"2019111821285511600_B4","first-page":"95","article-title":"Platelet function in the myelodysplastic syndromes.","volume":"71","author":"Mittelman","year":"2000","journal-title":"Int J Hematol."},{"key":"2019111821285511600_B5","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0955-3886(00)00004-7","article-title":"Comparison of platelet immunity in patients with SLE and with ITP.","volume":"22","author":"Lazarus","year":"2000","journal-title":"Transfus Sci."},{"key":"2019111821285511600_B6","doi-asserted-by":"crossref","first-page":"1575","DOI":"10.1007\/BF02285211","article-title":"Course of thrombocytopenia of chronic liver disease after transjugular intrahepatic portosystemic shunts (TIPS): a retrospective analysis.","volume":"40","author":"Lawrence","year":"1995","journal-title":"Dig Dis Sci."},{"key":"2019111821285511600_B7","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1016\/1010-7940(92)90003-G","article-title":"Complications from intra-aortic balloon counterpulsation: a review of 303 cardiac surgical patients.","volume":"6","author":"Alvarez","year":"1992","journal-title":"Eur J Cardiothorac Surg."},{"key":"2019111821285511600_B8","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0002-9343(98)00128-4","article-title":"Association of thrombocytopenia with the use of intra-aortic balloon pumps.","volume":"105","author":"Vonderheide","year":"1998","journal-title":"Am J Med."},{"key":"2019111821285511600_B9","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1046\/j.1537-2995.1994.341195065031.x","article-title":"A prospective study of symptomatic bacteremia following platelet transfusion and of its management.","volume":"34","author":"Chiu","year":"1994","journal-title":"Transfusion."},{"key":"2019111821285511600_B10","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1097\/00000441-199405000-00005","article-title":"Case report: fatal Staphylococcus aureus sepsis from single-donor platelet transfusion.","volume":"307","author":"Davda","year":"1994","journal-title":"Am J Med Sci."},{"key":"2019111821285511600_B11","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1046\/j.1537-2995.1990.30390194340.x","article-title":"Febrile reactions after platelet transfusion: the effect of single versus multiple donors.","volume":"30","author":"Chambers","year":"1990","journal-title":"Transfusion."},{"key":"2019111821285511600_B12","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0268-960X(98)90001-7","article-title":"Diagnosis and treatment of patients refractory to platelet transfusions.","volume":"12","author":"Contreras","year":"1998","journal-title":"Blood Rev."},{"key":"2019111821285511600_B13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1046\/j.1423-0410.1997.73301911.x","article-title":"Management of alloimmunized, refractory patients in need of platelet transfusions.","volume":"73","author":"Engelfriet","year":"1997","journal-title":"Vox Sang."},{"key":"2019111821285511600_B14","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1097\/00062752-199502060-00015","article-title":"Causes of refractoriness to platelet transfusion.","volume":"2","author":"Friedberg","year":"1995","journal-title":"Curr Opin Hematol."},{"key":"2019111821285511600_B15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1423-0410.1999.7610001.x","article-title":"Prevention and management of platelet transfusion refractoriness.","volume":"76","author":"Novotny","year":"1999","journal-title":"Vox Sang."},{"key":"2019111821285511600_B16","doi-asserted-by":"crossref","first-page":"2493","DOI":"10.1182\/blood.V76.12.2493.2493","article-title":"Interleukin-1 beta (IL-1 beta) induces thrombocytosis in mice: possible implication of IL-6.","volume":"76","author":"Kimura","year":"1990","journal-title":"Blood."},{"key":"2019111821285511600_B17","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1016\/0092-8674(94)90450-2","article-title":"Identification and cloning of a megakaryocyte growth and development factor that is a ligand for the cytokine receptor Mpl.","volume":"77","author":"Bartley","year":"1994","journal-title":"Cell."},{"key":"2019111821285511600_B18","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1038\/369565a0","article-title":"Cloning and expression of murine thrombopoietin cDNA and stimulation of platelet production in vivo.","volume":"369","author":"Lok","year":"1994","journal-title":"Nature."},{"key":"2019111821285511600_B19","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1038\/369533a0","article-title":"Stimulation of megakaryocytopoiesis and thrombopoiesis by the c-Mpl ligand.","volume":"369","author":"de Sauvage","year":"1994","journal-title":"Nature."},{"key":"2019111821285511600_B20","doi-asserted-by":"crossref","first-page":"11104","DOI":"10.1073\/pnas.91.23.11104","article-title":"The purification of megapoietin: a physiological regulator of megakaryocyte growth and platelet production.","volume":"91","author":"Kuter","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821285511600_B21","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/oxfordjournals.jbchem.a124883","article-title":"Purification and characterization of thrombopoietin.","volume":"118","author":"Kato","year":"1995","journal-title":"J Biochem."},{"key":"2019111821285511600_B22","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1002\/jcp.1041280311","article-title":"In vitro actions on hemopoietic cells of recombinant murine GM-CSF purified after production in Escherichia coli: comparison with purified native GM-CSF.","volume":"128","author":"Metcalf","year":"1986","journal-title":"J Cell Physiol."},{"key":"2019111821285511600_B23","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1182\/blood.V82.1.84.bloodjournal82184","article-title":"Effects of the recombinant hematopoietic growth factors interleukin-3, interleukin-6, stem cell factor, and leukemia inhibitory factor on the megakaryocytic differentiation of CD34+ cells.","volume":"82","author":"Debili","year":"1993","journal-title":"Blood."},{"key":"2019111821285511600_B24","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood.V83.6.1499.1499","article-title":"Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin.","volume":"83","author":"Leonard","year":"1994","journal-title":"Blood."},{"key":"2019111821285511600_B25","first-page":"1","article-title":"Hemopoietic responses in mice injected with purified recombinant murine GM-CSF.","volume":"15","author":"Metcalf","year":"1987","journal-title":"Exp Hematol."},{"key":"2019111821285511600_B26","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1182\/blood.V68.1.46.bloodjournal68146","article-title":"Effects of purified bacterially synthesized murine multi-CSF (IL-3) on hematopoiesis in normal adult mice.","volume":"68","author":"Metcalf","year":"1986","journal-title":"Blood."},{"key":"2019111821285511600_B27","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1200\/JCO.1994.12.4.707","article-title":"Effects of interleukin-1 alpha on carboplatin-induced thrombocytopenia in patients with recurrent ovarian cancer.","volume":"12","author":"Vadhan-Raj","year":"1994","journal-title":"J Clin Oncol."},{"key":"2019111821285511600_B28","first-page":"1459","article-title":"Interleukin 3 in the treatment of chemotherapy induced thrombocytopenia.","volume":"5","author":"Leonardi","year":"1998","journal-title":"Oncol Rep."},{"key":"2019111821285511600_B29","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1182\/blood.V85.9.2347.bloodjournal8592347","article-title":"Thrombopoietic effects and toxicity of interleukin-6 in patients with ovarian cancer before and after chemotherapy: a multicentric placebo-controlled, randomized phase Ib study.","volume":"85","author":"D'Hondt","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B30","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1182\/blood.V87.9.3615.bloodjournal8793615","article-title":"A phase I trial of recombinant human interleukin-11 (neumega rhIL-11 growth factor) in women with breast cancer receiving chemotherapy.","volume":"87","author":"Gordon","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B31","first-page":"3607","article-title":"A randomized placebo-controlled trial of recombinant human interleukin-11 in cancer patients with severe thrombocytopenia due to chemotherapy.","volume":"87","author":"Tepler","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B32","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1056\/NEJM199303183281103","article-title":"The effects of treatment with interleukin-1 alpha on platelet recovery after high-dose carboplatin.","volume":"328","author":"Smith","year":"1993","journal-title":"N Engl J Med."},{"key":"2019111821285511600_B33","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S1083-8791(98)50002-X","article-title":"A randomized trial of recombinant human interleukin-11 following autologous bone marrow transplantation with peripheral blood progenitor cell support in patients with breast cancer.","volume":"4","author":"Vredenburgh","year":"1998","journal-title":"Biol Blood Marrow Transplant."},{"key":"2019111821285511600_B34","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1182\/blood.V90.6.2148.2148_2148_2159","article-title":"Adult mice with targeted mutation of the interleukin-11 receptor (IL11Ra) display normal hematopoiesis.","volume":"90","author":"Nandurkar","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B35","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nm0398-303","article-title":"Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation.","volume":"4","author":"Robb","year":"1998","journal-title":"Nat Med."},{"key":"2019111821285511600_B36","doi-asserted-by":"crossref","first-page":"3066","DOI":"10.1182\/blood.V85.11.3066.bloodjournal85113066","article-title":"A phase I trial of recombinant human interleukin-6 in patients with myelodysplastic syndromes and thrombocytopenia.","volume":"85","author":"Gordon","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B37","first-page":"935","article-title":"Phase I multicenter trial of interleukin 6 therapy after autologous bone marrow transplantation in advanced breast cancer.","volume":"15","author":"Lazarus","year":"1995","journal-title":"Bone Marrow Transplant."},{"key":"2019111821285511600_B38","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1182\/blood.V86.3.900.900","article-title":"Recombinant human interleukin-6 induces a rapid and reversible anemia in cancer patients.","volume":"86","author":"Nieken","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B39","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1182\/blood.V88.3.803.803","article-title":"Low levels of erythroid and myeloid progenitors in thrombopoietin- and c-mpl-deficient mice.","volume":"88","author":"Carver-Moore","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B40","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1182\/blood.V91.8.2745.2745_2745_2752","article-title":"Cytokine production and function in c-mpl-deficient mice: no physiologic role for interleukin-3 in residual megakaryocyte and platelet production.","volume":"91","author":"Gainsford","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B41","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood.V95.2.528","article-title":"The residual megakaryocyte and platelet production in c-mpl-deficient mice is not dependent on the actions of interleukin-6, interleukin-11, or leukemia inhibitory factor.","volume":"95","author":"Gainsford","year":"2000","journal-title":"Blood."},{"key":"2019111821285511600_B42","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1159\/000205503","article-title":"Demonstration and some properties of human thrombopoietin in thrombocythaemic sera.","volume":"20","author":"Kelemen","year":"1958","journal-title":"Acta Haematol."},{"key":"2019111821285511600_B43","first-page":"145","article-title":"The oncogene V-MPL, a putative truncated cytokine receptor which immortalized hemtopoietic progenitors.","volume":"33","author":"Wendling","year":"1991","journal-title":"Nouv Rev Fr Hematol."},{"key":"2019111821285511600_B44","doi-asserted-by":"crossref","first-page":"5640","DOI":"10.1073\/pnas.89.12.5640","article-title":"Molecular cloning and characterization of MPL, the human homolog of the v-mpl oncogene: identification of a member of the hematopoietic growth factor receptor superfamily.","volume":"89","author":"Vigon","year":"1992","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821285511600_B45","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.1182\/blood.V82.5.1395.1395","article-title":"Oligodeoxynucleotides antisense to the proto-oncogene c-mpl specifically inhibit in vitro megakaryocytopoiesis.","volume":"82","author":"Methia","year":"1993","journal-title":"Blood."},{"key":"2019111821285511600_B46","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/0014-5793(94)01008-0","article-title":"Molecular cloning and chromosomal localization of the human thrombopoietin gene.","volume":"353","author":"Sohma","year":"1994","journal-title":"FEBS Letters."},{"key":"2019111821285511600_B47","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1007\/978-1-4612-3958-1_13","article-title":"The biological significance of truncated and full-length forms of Mpl ligand.","volume-title":"Thrombopoiesis and Thrombopoietins: Molecular, Cellular, Preclinical, and Clinical Biology.","author":"Foster","year":"1997"},{"key":"2019111821285511600_B48","doi-asserted-by":"crossref","first-page":"13023","DOI":"10.1073\/pnas.91.26.13023","article-title":"Human thrombopoietin: gene structure, cDNA sequence, expression, and chromosomal localization.","volume":"91","author":"Foster","year":"1994","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821285511600_B49","doi-asserted-by":"crossref","first-page":"478","DOI":"10.1111\/j.1365-2141.1999.01359.x","article-title":"The physiological response of thrombopoietin (c-Mpl ligand) to thrombocytopenia in the rat.","volume":"105","author":"Yang","year":"1999","journal-title":"Br J Haematol."},{"key":"2019111821285511600_B50","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1182\/blood.V87.2.567.bloodjournal872567","article-title":"Thrombopoietin in thrombocytopenic mice: evidence against regulation at the mRNA level and for a direct regulatory role of platelets.","volume":"87","author":"Stoffel","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B51","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1182\/blood.V87.6.2154.bloodjournal8762154","article-title":"Regulation of thrombopoietin levels by c-mpl-mediated binding to platelets.","volume":"87","author":"Fielder","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B52","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1182\/blood.V84.5.1464.1464","article-title":"Appearance of a megakaryocyte growth-promoting activity, megapoietin, during acute thrombocytopenia in the rabbit.","volume":"84","author":"Kuter","year":"1994","journal-title":"Blood."},{"key":"2019111821285511600_B53","doi-asserted-by":"crossref","first-page":"2720","DOI":"10.1182\/blood.V85.10.2720.bloodjournal85102720","article-title":"The reciprocal relationship of thrombopoietin (c-Mpl ligand) to changes in the platelet mass during busulfan-induced thrombocytopenia in the rabbit.","volume":"85","author":"Kuter","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B54","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/stem.5530140711","article-title":"The physiology of platelet production.","volume":"14","author":"Kuter","year":"1996","journal-title":"Stem Cells."},{"key":"2019111821285511600_B55","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1046\/j.1365-2141.1999.01571.x","article-title":"Interaction of thrombopoietin with the platelet c-mpl receptor in plasma: binding, internalization, stability and pharmacokinetics.","volume":"106","author":"Li","year":"1999","journal-title":"Br J Haematol."},{"key":"2019111821285511600_B56","doi-asserted-by":"crossref","first-page":"1896","DOI":"10.1182\/blood.V89.6.1896","article-title":"Human platelets display high-affinity receptors for thrombopoietin.","volume":"89","author":"Broudy","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B57","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1046\/j.1537-2995.2002.00047.x","article-title":"Human plasma thrombopoietin levels are regulated by binding to platelet thrombopoietin receptors in vivo.","volume":"42","author":"Scheding","year":"2002","journal-title":"Transfusion."},{"key":"2019111821285511600_B58","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V89.1.101","article-title":"Localization and regulation of thrombopoietin mRNa expression in human kidney, liver, bone marrow, and spleen using in situ hybridization.","volume":"89","author":"Sungaran","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B59","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1182\/blood.V92.6.2189","article-title":"Primary role of the liver in thrombopoietin production shown by tissue-specific knockout.","volume":"92","author":"Quin","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B60","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0168-8278(97)80291-7","article-title":"Is inadequate thrombopoietin production a major cause of thrombocytopenia in cirrhosis of the liver?","volume":"27","author":"Peck-Radosavljevic","year":"1997","journal-title":"J Hepatol."},{"key":"2019111821285511600_B61","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1182\/blood.V95.3.795.003k25_795_801","article-title":"Thrombopoietin induces rapid resolution of thrombocytopenia after orthotopic liver transplantation through increased platelet production.","volume":"95","author":"Peck-Radosavljevic","year":"2000","journal-title":"Blood."},{"key":"2019111821285511600_B62","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1038\/369568a0","article-title":"Promotion of megakaryocyte progenitor expansion and differentiation by the c-Mpl ligand thrombopoietin.","volume":"369","author":"Kaushansky","year":"1994","journal-title":"Nature."},{"key":"2019111821285511600_B63","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1182\/blood.V85.7.1719.bloodjournal8571719","article-title":"Thrombopoietin (c-mpl ligand) acts synergistically with erythropoietin, stem cell factor, and interleukin-11 to enhance murine megakaryocyte colony growth and increases megakaryocyte ploidy in vitro.","volume":"85","author":"Broudy","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B64","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/stem.150033","article-title":"Mpl ligand (MGDF) alone and in combination with stem cell factor (SCF) promotes proliferation and survival of human megakaryocyte, erythroid and granulocyte\/macrophage progenitors.","volume":"15","author":"Rasko","year":"1997","journal-title":"Stem Cells."},{"key":"2019111821285511600_B65","doi-asserted-by":"crossref","first-page":"4544","DOI":"10.1182\/blood.V87.11.4544.bloodjournal87114544","article-title":"Thrombopoietin, the ligand for the Mpl receptor, synergizes with steel factor and other early acting cytokines in supporting proliferation of primitive hematopoietic progenitors of mice.","volume":"87","author":"Ku","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B66","doi-asserted-by":"crossref","first-page":"4998","DOI":"10.1182\/blood.V87.12.4998.bloodjournal87124998","article-title":"The effect of thrombopoietin on the proliferation and differentiation of murine hematopoietic stem cells.","volume":"87","author":"Sitnicka","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B67","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1084\/jem.183.2.651","article-title":"Physiological regulation of early and late stages of megakaryocytopoiesis by thrombopoietin.","volume":"183","author":"de Sauvage","year":"1996","journal-title":"J Exp Med."},{"key":"2019111821285511600_B68","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/S0022-2143(98)90057-9","article-title":"Regulation of megakaryocytopoiesis and platelet production: lessons from animal models.","volume":"131","author":"de Sauvage","year":"1998","journal-title":"J Lab Clin Med."},{"key":"2019111821285511600_B69","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/stem.5530140716","article-title":"Studies of the c-Mpl thrombopoietin receptor through gene disruption and activation.","volume":"14","author":"Alexander","year":"1996","journal-title":"Stem Cells."},{"key":"2019111821285511600_B70","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood.V87.6.2162.bloodjournal8762162","article-title":"Deficiencies in progenitor cells of multiple hematopoietic lineages and defective megakaryocytopoiesis in mice lacking the thrombopoietic receptor c-Mpl.","volume":"87","author":"Alexander","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B71","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1126\/science.8073287","article-title":"Thrombocytopenia in c-mpl-deficient mice.","volume":"265","author":"Gurney","year":"1994","journal-title":"Science."},{"key":"2019111821285511600_B72","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/S0301-472X(00)00504-X","article-title":"Granulocyte-macrophage colony-stimulating factor is not responsible for residual thrombopoiesis in mpl null mice.","volume":"28","author":"Scott","year":"2000","journal-title":"Exp Hematol."},{"key":"2019111821285511600_B73","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1073\/pnas.95.3.1195","article-title":"Hematopoietic stem cell deficiencies in mice lacking c-Mpl, the receptor for thrombopoietin.","volume":"95","author":"Kimura","year":"1998","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821285511600_B74","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1046\/j.1365-2141.1996.d01-1920.x","article-title":"The role of megakaryocyte growth and development factor in terminal stages of thrombopoiesis.","volume":"95","author":"Choi","year":"1996","journal-title":"Br J Haematol."},{"key":"2019111821285511600_B75","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1055\/s-0038-1649979","article-title":"Modulation of platelet activation in vitro by thrombopoietin.","volume":"74","author":"Kojima","year":"1995","journal-title":"Thromb Haemost."},{"key":"2019111821285511600_B76","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/0014-5793(95)01072-M","article-title":"Thrombopoietin, c-Mpl ligand, induces tyrosine phosphorylation of Tyk2, JAK2, and STAT3, and enhances agonists-induced aggregation in platelets in vitro.","volume":"374","author":"Ezumi","year":"1995","journal-title":"FEBS Lett."},{"key":"2019111821285511600_B77","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/BF02982078","article-title":"The end is just the beginning: megakaryocyte apoptosis and platelet release.","volume":"74","author":"Li","year":"2001","journal-title":"Int J Hematol."},{"key":"2019111821285511600_B78","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood.V68.1.162.bloodjournal681162","article-title":"Purified colony-stimulating factors enhance the survival of human neutrophils and eosinophils in vitro: a rapid and sensitive microassay for colony-stimulating factors.","volume":"68","author":"Begley","year":"1986","journal-title":"Blood."},{"key":"2019111821285511600_B79","doi-asserted-by":"crossref","first-page":"1220","DOI":"10.1172\/JCI112705","article-title":"Recombinant human granulocyte-macrophage colony-stimulating factor stimulates in vitro mature human neutrophil and eosinophil function, surface receptor expression, and survival.","volume":"78","author":"Lopez","year":"1986","journal-title":"J Clin Invest."},{"key":"2019111821285511600_B80","doi-asserted-by":"crossref","first-page":"4158","DOI":"10.1182\/blood.V87.10.4158.bloodjournal87104158","article-title":"Relative reactivity of platelets from thrombopoietin- and interleukin-6-treated dogs.","volume":"87","author":"Peng","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B81","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1182\/blood.V87.5.1833.1833","article-title":"Regulation of platelet production and function by megakaryocyte growth and development factor in nonhuman primates.","volume":"87","author":"Harker","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B82","doi-asserted-by":"crossref","first-page":"27790","DOI":"10.1074\/jbc.M000540200","article-title":"Dual regulation of platelet protein kinase B.","volume":"275","author":"Kroner","year":"2000","journal-title":"J Biol Chem."},{"key":"2019111821285511600_B83","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1046\/j.1537-2995.1999.39399219281.x","article-title":"Effect of recombinant human megakaryocyte growth and development factor coupled with polyethylene glycol on the platelet storage lesion.","volume":"39","author":"Snyder","year":"1999","journal-title":"Transfusion."},{"key":"2019111821285511600_B84","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1046\/j.1537-2995.2000.40080976.x","article-title":"Thrombopoietin and the TPO receptor during platelet storage.","volume":"40","author":"Xia","year":"2000","journal-title":"Transfusion."},{"key":"2019111821285511600_B85","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin.","volume":"98","author":"Li","year":"2001","journal-title":"Blood."},{"key":"2019111821285511600_B86","doi-asserted-by":"crossref","first-page":"4486","DOI":"10.1182\/blood.V86.12.4486.bloodjournal86124486","article-title":"Pegylated megakaryocyte growth and development factor abrogates the lethal thrombocytopenia associated with carboplatin and irradiation in mice.","volume":"86","author":"Hokom","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B87","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1097\/00062752-199704050-00003","article-title":"Mechanism of action and clinical trials of Mpl ligand.","volume":"4","author":"Sheridan","year":"1997","journal-title":"Curr Opin Hematol."},{"key":"2019111821285511600_B88","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S0037-1963(00)90049-0","article-title":"Biologic and structural differences of thrombopoietic growth factors.","volume":"37","author":"Begley","year":"2000","journal-title":"Semin Hematol."},{"key":"2019111821285511600_B89","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1182\/blood.V88.2.511.bloodjournal882511","article-title":"Dose-response effects of pegylated human megakaryocyte growth and development factor on platelet production and function in nonhuman primates.","volume":"88","author":"Harker","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B90","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1182\/blood.V86.3.971.971","article-title":"Megakaryocyte growth and development factor ameliorates carboplatin-induced thrombocytopenia in mice.","volume":"86","author":"Ulich","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B91","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1182\/blood.V89.1.155","article-title":"Prevention of thrombocytopenia and neutropenia in a nonhuman primate model of marrow suppressive chemotherapy by combining pegylated recombinant human megakaryocyte growth and development factor and recombinant human granulocyte colony-stimulating factor.","volume":"89","author":"Harker","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B92","doi-asserted-by":"crossref","first-page":"722","DOI":"10.1046\/j.1365-2141.1996.d01-1842.x","article-title":"Effect of recombinant human thrombopoietin in nonhuman primates with chemotherapy-induced thrombocytopenia.","volume":"94","author":"Akahori","year":"1996","journal-title":"Br J Haematol."},{"key":"2019111821285511600_B93","doi-asserted-by":"crossref","first-page":"2565","DOI":"10.1182\/blood.V90.7.2565","article-title":"The efficacy of single-dose administration of thrombopoietin with coadministration of either granulocyte\/macrophage or granulocyte colony- stimulating factor in myelosuppressed rhesus monkeys.","volume":"90","author":"Neelis","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B94","first-page":"580a","article-title":"Promegapoietin, a chimeric growth factor for megakaryocyte and platelet restoration [abstract].","volume":"90","author":"Giri","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B95","doi-asserted-by":"crossref","first-page":"1696","DOI":"10.1126\/science.276.5319.1696","article-title":"Peptide agonist of the thrombopoietin receptor as potent as the natural cytokine.","volume":"276","author":"Cwirla","year":"1997","journal-title":"Science."},{"key":"2019111821285511600_B96","first-page":"675a","article-title":"Discovery and characterization of a selective, non-peptidyl thrombopoietin receptor agonist [abstract].","volume":"96","author":"Erickson-Miller","year":"2000","journal-title":"Blood."},{"key":"2019111821285511600_B97","doi-asserted-by":"crossref","first-page":"7569","DOI":"10.1073\/pnas.96.13.7569","article-title":"Activation of erythropoietin receptor in the absence of hormone by a peptide that binds to a domain different from the hormone binding site.","volume":"96","author":"Naranda","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821285511600_B98","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1056\/NEJM199702063360603","article-title":"Effects of polyethylene glycol-conjugated recombinant human megakaryocyte growth and development factor on platelet counts after chemotherapy for lung cancer.","volume":"336","author":"Fanucchi","year":"1997","journal-title":"N Engl J Med."},{"key":"2019111821285511600_B99","first-page":"3118","article-title":"Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer.","volume":"89","author":"Basser","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B100","first-page":"73a","article-title":"A randomized, placebo-controlled, blinded, dose scheduling trial of pegylated recombinant human megakaryocyte growth and development factor (PEG-HUMGDF) with filgrastim support in non-small cell lung cancer (NSCLC) patients treated with paclitaxel and carboplatin during multiple cycles of chemotherapy [abstract].","volume":"17","author":"Crawford","year":"1998","journal-title":"Proceedings ASCO."},{"key":"2019111821285511600_B101","first-page":"448a","article-title":"Phase I-II investigtion of recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [abstract].","volume":"88","author":"Vadhan-Raj","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B102","doi-asserted-by":"crossref","first-page":"673","DOI":"10.7326\/0003-4819-126-9-199705010-00001","article-title":"Stimulation of megakaryocyte and platelet production by a single dose of recombinant human thrombopoietin in patients with cancer.","volume":"126","author":"Vadhan-Raj","year":"1997","journal-title":"Ann Int Med."},{"key":"2019111821285511600_B103","first-page":"580a","article-title":"Recombinant human thrombopoietin (rhTPO) attenuates high-dose carboplatin (C)-induced thrombocytopenia in patients with gynecological malignancy [abstract].","volume":"90","author":"Vadhan-Raj","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B104","doi-asserted-by":"crossref","first-page":"364","DOI":"10.7326\/0003-4819-132-5-200003070-00005","article-title":"Recombinant human thrombopoietin attenuates carboplatin-induced severe thrombocytopenia and the need for platelet transfusions in patients with gynecologic cancer.","volume":"132","author":"Vadhan-Raj","year":"2000","journal-title":"Ann Intern Med."},{"key":"2019111821285511600_B105","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(96)04471-6","article-title":"Thrombopoietic effects of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in patients with advanced cancer.","volume":"348","author":"Basser","year":"1996","journal-title":"Lancet."},{"key":"2019111821285511600_B106","doi-asserted-by":"crossref","first-page":"2852","DOI":"10.1200\/JCO.2000.18.15.2852","article-title":"Enhancement of platelet recovery after myelosuppressive chemotherapy by recombinant human megakaryocyte growth and development factor in patients with advanced cancer.","volume":"18","author":"Basser","year":"2000","journal-title":"J Clin Oncol."},{"key":"2019111821285511600_B107","first-page":"76a","article-title":"A randomized, double blind, placebo-controlled, dose finding, efficacy and safety study of PEG-rHuMGDF (M) in non-Hodgkin's lymphoma (NHL) patients (pts) treated with ICE (ifosfamide, carboplatin and etoposide) [abstract].","volume":"17","author":"Moskowitz","year":"1998","journal-title":"J Clin Oncol."},{"key":"2019111821285511600_B108","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1182\/blood.V88.9.3288.bloodjournal8893288","article-title":"Administration of pegylated recombinant human megakaryocyte growth and development factor to humans stimulates the production of functional platelets that show no evidence of in vivo activation.","volume":"88","author":"O'Malley","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B109","first-page":"52a","article-title":"Schedule-dependent reduction in thrombocytopenia by recombinant human thrombopoietin (rhTPO) in patients with sarcoma receiving high dose chemotherapy (CT) with adriamycin (A) and ifosfamide (I) [abstract].","volume":"18","author":"Vadhan-Raj","year":"1999","journal-title":"J Clin Oncol."},{"key":"2019111821285511600_B110","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/j.1600-0609.1993.tb00085.x","article-title":"A retrospective analysis of bleeding complications in 438 patients with acute leukaemia during the years 1972-1991.","volume":"50","author":"Tornebohm","year":"1993","journal-title":"Eur J Haematol."},{"key":"2019111821285511600_B111","first-page":"600","article-title":"Causes of initial remission induction failure in patients with acute myeloid leukemia and myelodysplastic syndromes.","volume":"10","author":"Anderlini","year":"1996","journal-title":"Leukemia."},{"key":"2019111821285511600_B112","doi-asserted-by":"crossref","first-page":"3694","DOI":"10.1182\/blood.V94.11.3694","article-title":"A randomized, double-blind, placebo-controlled study with pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) as an adjunct to chemotherapy for adults with de novo acute myeloid leukemia.","volume":"94","author":"Archimbaud","year":"1999","journal-title":"Blood."},{"key":"2019111821285511600_B113","first-page":"447a","article-title":"A randomized, double-blind, placebo-controlled study using PEG-rHuMGDF as an adjunct to chemotherapy for adults with de-novo acute myeloid leukemia (AML): early results [abstract].","volume":"99","author":"Archimbaud","year":"1996","journal-title":"Blood."},{"key":"2019111821285511600_B114","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1182\/blood.V95.8.2530","article-title":"A double-blind, placebo-controlled trial of pegylated recombinant human megakaryocyte growth and development factor as an adjunct to induction and consolidation therapy for patients with acute myeloid leukemia.","volume":"95","author":"Schiffer","year":"2000","journal-title":"Blood."},{"key":"2019111821285511600_B115","first-page":"616a","article-title":"A pilot study of recombinant human thrombopoietin (rh-TPO) and GM-CSF following induction therapy in patients older than 55 years with acute myeloid leukemia (AML) [abstract].","volume":"92","author":"Cripe","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B116","first-page":"580a","article-title":"Effects of PEGylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) before high dose chemotherapy (HDC) with peripheral blood progenitor cell (PBPC) support [abstract].","volume":"90","author":"Glaspy","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B117","first-page":"171a","article-title":"Safety and biological effect of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologous peripheral blood progenitor cell transplantation (PBPC) [abstract].","volume":"90","author":"Bolwell","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B118","first-page":"580a","article-title":"Randomized, double-blind, placebo-controlled trial of pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients following autologous bone marrow transplantation [abstract].","volume":"90","author":"Beveridge","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B119","first-page":"262a","article-title":"Safety and activity of recombinant human thrombopoietin (rhTPO) in patients (pts) with delayed platelet recovery (DPR) [abstract].","volume":"90","author":"Nash","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B120","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S1083-8791(00)70049-8","article-title":"A phase I trial of recombinant human thrombopoietin in patients with delayed platelet recovery after hematopoietic stem cell transplantation.","volume":"6","author":"Nash","year":"2000","journal-title":"Biol Blood Marrow Transplant."},{"key":"2019111821285511600_B121","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1182\/blood.V93.9.2798.409k26_2798_2806","article-title":"Recombinant human thrombopoietin in combination with granulocyte colony-stimulating factor enhances mobilization of peripheral blood progenitor cells, increases peripheral blood platelet concentration, and accelerates hematopoietic recovery following high-dose chemotherapy.","volume":"93","author":"Somlo","year":"1999","journal-title":"Blood."},{"key":"2019111821285511600_B122","first-page":"97a","article-title":"Recombinant human thrombopoietin (rhTPO) for mobilization of peripheral blood progenitor cells (PBPC) for autologous transplantation in breast cancer: preliminary results of a phase I trial [abstract].","volume":"90","author":"Gajewski","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B123","first-page":"682a","article-title":"A randomized, placebo-controlled, phase II trial of recombinant human thrombopoietin (rhTPO) in subjects undergoing high dose chemotherapy (HDC) and PBPC transplant [abstract].","volume":"92","author":"Linker","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B124","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0037-1963(00)90051-9","article-title":"Thrombopoietin in the treatment of acute myeloid leukemia and in stem-cell transplantation.","volume":"37","author":"Linker","year":"2000","journal-title":"Semin Hematol."},{"key":"2019111821285511600_B125","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1038\/sj.bmt.1702465","article-title":"Phase 1 study of pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) in breast cancer patients after autologous peripheral blood progenitor cell (PBPC) transplantation.","volume":"26","author":"Bolwell","year":"2000","journal-title":"Bone Marrow Transplant."},{"key":"2019111821285511600_B126","doi-asserted-by":"crossref","first-page":"3308","DOI":"10.1182\/blood.V86.9.3308.bloodjournal8693308","article-title":"Accelerated reconstitution of platelets and erythrocytes after syngeneic transplantation of bone marrow cells derived from thrombopoietin pretreated donor mice.","volume":"86","author":"Fibbe","year":"1995","journal-title":"Blood."},{"key":"2019111821285511600_B127","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1365-2141.2000.01916.x","article-title":"Megakaryopoiesis in vitro in myelodysplastic syndromes and acute myeloid leukaemia: effect of pegylated recombinant human megakaryocyte growth and development factor in combination with other growth factors.","volume":"108","author":"Liu Yin","year":"2000","journal-title":"Br J Haematol."},{"key":"2019111821285511600_B128","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/S0145-2126(98)00028-9","article-title":"Analysis of megakaryocyte growth and development factor (thrombopoietin) effects on blast cell and megakaryocyte growth in myelodysplasia.","volume":"22","author":"Fontenay-Roupie","year":"1998","journal-title":"Leuk Res."},{"key":"2019111821285511600_B129","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1097\/00062752-199805000-00010","article-title":"Thrombopoietin levels after chemotherapy and in naturally occurring human diseases.","volume":"5","author":"Nichol","year":"1998","journal-title":"Curr Opin Hematol."},{"key":"2019111821285511600_B130","first-page":"296a","article-title":"Pegylated recombinant human megakaryocyte growth and development factor (PEG-rHuMGDF) increased platelet counts (plt) in patients with aplastic anemia (AA) and myelodysplastic syndrome (MDS) [abstract].","volume":"96","author":"Komatsu","year":"2000","journal-title":"Blood."},{"key":"2019111821285511600_B131","doi-asserted-by":"crossref","first-page":"4427","DOI":"10.1182\/blood.V91.12.4427","article-title":"Treatment of thrombocytopenia in chimpanzees infected with human immunodeficiency virus by pegylated recombinant human megakaryocyte growth and development factor.","volume":"91","author":"Harker","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B132","first-page":"707a","article-title":"Correction of thrombocytopenia and ineffective platelet production in patients infected with human immunodeficiency virus (HIV) by PEG-rHuMGDF therapy [abstract].","volume":"92(suppl 1)","author":"Harker","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B133","first-page":"299a","article-title":"Biological effect of pegylated recombinant megakaryocyte growth and development factor (PEG-MGDF) in patients with idiopathic thrombocytopenic purpura [abstract].","volume":"98","author":"Dan","year":"2001","journal-title":"Blood."},{"key":"2019111821285511600_B134","first-page":"180b","article-title":"Cyclic thrombocytopenia with platelet auto-antibodies: response to PEG-rHu megakaryocyte growth and development factor [abstract].","volume":"92","author":"Rice","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B135","first-page":"817","article-title":"The effect of massive liver resection on platelet kinetics in the rat.","volume":"86","author":"Siemensma","year":"1975","journal-title":"J Lab Clin Med."},{"key":"2019111821285511600_B136","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1002\/stem.5530160726","article-title":"The use of PEG-rhuMGDF in platelet apheresis.","volume":"16","author":"Kuter","year":"1998","journal-title":"Stem Cells."},{"key":"2019111821285511600_B137","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/S0003-4975(98)00807-8","article-title":"Recombinant human megakaryocyte growth and development factor attenuates postbypass thrombocytopenia.","volume":"66","author":"Nakamura","year":"1998","journal-title":"Ann Thorac Surg."},{"key":"2019111821285511600_B138","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1046\/j.1365-2141.1997.1212937.x","article-title":"Multilineage mobilization of peripheral blood progenitor cells in humans following administration of PEG-rHuMGDF.","volume":"97","author":"Rasko","year":"1997","journal-title":"Br J Haematol."},{"key":"2019111821285511600_B139","first-page":"207","article-title":"Thrombopoietin mobilizes CD34+ cell subsets into peripheral blood and expands multilineage progenitors in bone marrow of cancer patients with normal hematopoiesis.","volume":"26","author":"Murray","year":"1998","journal-title":"Exp Hematol."},{"key":"2019111821285511600_B140","doi-asserted-by":"crossref","first-page":"8126","DOI":"10.1073\/pnas.96.14.8126","article-title":"Sustained ex vivo expansion of hematopoietic stem cells mediated by thrombopoietin.","volume":"96","author":"Yagi","year":"1999","journal-title":"Proc Natl Acad Sci U S A."},{"key":"2019111821285511600_B141","doi-asserted-by":"crossref","first-page":"2644","DOI":"10.1182\/blood.V89.8.2644","article-title":"Extensive amplification and self-renewal of human primitive hematopoietic stem cells from cord blood.","volume":"89","author":"Piacibello","year":"1997","journal-title":"Blood."},{"key":"2019111821285511600_B142","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1182\/blood.V98.5.1339","article-title":"Thrombopoietin therapy increases platelet yields in healthy platelet donors.","volume":"98","author":"Kuter","year":"2001","journal-title":"Blood."},{"key":"2019111821285511600_B143","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.1182\/blood.V98.5.1346","article-title":"Prophylactic platelet transfusions from healthy apheresis platelet donors undergoing treatment with thrombopoietin.","volume":"98","author":"Goodnough","year":"2001","journal-title":"Blood."},{"key":"2019111821285511600_B144","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1182\/blood.V92.5.1586","article-title":"A single dose of thrombopoietin shortly after myelosuppressive total body irradiation prevents pancytopenia in mice by promoting short-term multilineage spleen-repopulating cells at the transient expense of bone marrow-repopulating cells.","volume":"92","author":"Neelis","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B145","first-page":"265","article-title":"Thrombopoietin expands erythroid, granulocyte-macrophage, and megakaryocytic progenitor cells in normal and myelosuppressed mice.","volume":"24","author":"Kaushansky","year":"1996","journal-title":"Exp Hematol."},{"key":"2019111821285511600_B146","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1002\/stem.5530150813","article-title":"Thrombopoietin: more than a lineage-specific megakaryocyte growth factor.","volume":"15(suppl 1)","author":"Kaushansky","year":"1997","journal-title":"Stem Cells."},{"key":"2019111821285511600_B147","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/S0360-3016(98)00477-5","article-title":"Thrombopoietin promotes hematopoietic recovery and survival after high-dose whole body irradiation.","volume":"43","author":"Mouthon","year":"1999","journal-title":"Int J Radiat Oncol Biol Phys."},{"key":"2019111821285511600_B148","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1002\/stem.150043","article-title":"An analysis of the effects of combined treatment with rmGM-CSF and PEG- rHuMGDF in murine bone marrow transplant recipients.","volume":"15","author":"Molineux","year":"1997","journal-title":"Stem Cells."},{"key":"2019111821285511600_B149","first-page":"681a","article-title":"The appearance of anti-thrombopoietin antibody and circulating thrombopoietin-IgG complexes in a patient developing thrombocytopenia after the injection of PEG-rHuMGDF [abstract].","volume":"94","author":"Yang","year":"1999","journal-title":"Blood."},{"key":"2019111821285511600_B150","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor.","volume":"99","author":"Basser","year":"2002","journal-title":"Blood."},{"key":"2019111821285511600_B151","first-page":"27","article-title":"In Brief: Amgen Megagen.","volume":"60","author":"F-D-C Reports","year":"1998","journal-title":"The Pink Sheet."},{"key":"2019111821285511600_B152","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1056\/NEJM199712253372602","article-title":"The threshold for prophylactic platelet transfusions in adults with acute myeloid leukemia.","volume":"337","author":"Rebulla","year":"1997","journal-title":"N Engl J Med."},{"key":"2019111821285511600_B153","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1111\/j.1423-0410.2000.tb00058.x","article-title":"Trigger for platelet transfusion.","volume":"78(suppl 2)","author":"Rebulla","year":"2000","journal-title":"Vox Sang."},{"key":"2019111821285511600_B154","doi-asserted-by":"crossref","first-page":"3601","DOI":"10.1182\/blood.V91.10.3601","article-title":"Safety and cost effectiveness of a 10 \u00d7 10(9)\/L trigger for prophylactic platelet transfusions compared with the traditional 20 \u00d7 10(9)\/L trigger: a prospective comparative trial in 105 patients with acute myeloid leukemia.","volume":"91","author":"Wandt","year":"1998","journal-title":"Blood."},{"key":"2019111821285511600_B155","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1046\/j.1537-2995.2002.00056.x","article-title":"Whatever happened to thrombopoietin?","volume":"42","author":"Kuter","year":"2002","journal-title":"Transfusion."}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/10\/3457\/1252604\/h82202003457.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/100\/10\/3457\/1252604\/h82202003457.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,10]],"date-time":"2024-12-10T17:37:17Z","timestamp":1733852237000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/100\/10\/3457\/106321\/Recombinant-human-thrombopoietin-basic-biology-and"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,11,15]]},"references-count":155,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,11,15]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.v100.10.3457","relation":{},"ISSN":["1528-0020","0006-4971"],"issn-type":[{"value":"1528-0020","type":"electronic"},{"value":"0006-4971","type":"print"}],"subject":[],"published":{"date-parts":[[2002,11,15]]}}}